-
SLC22A16 DNA hypomethylation might be a compensation for DNA loss to maintain SLC22A16 elevation in GC. SLC22A16 might be a valuable prognostic marker in GC.
-
Allele C of ABCB1 and allele A of SLC22A16 tended to have a greater association with grade 3/4 febrile neutropenia.
-
Deletions in SLC22A16, a doxorubicin transporter, are associated with a failure to achieve event free survival in immunochemotherapy-treated diffuse large B-cell lymphoma.
-
findings may greatly contribute to the elucidation of the roles of the Oct and Myc proteins in osteoblast direct reprogramming. The results may also lead to establishment of novel regenerative therapy for various bone resorption diseases
-
Knockdown of CT2 reduced the growth and viability of acute myeloid leukemia cells with high expression of CT2 (OCI-AML2 and HL60), but not low expression. CT2 knockdown reduced basal oxygen consumption without a concomitant increase in glycolysis.
-
Both gene and protein expression of OCT6 were decreased in both CDDP-resistant lung cancer cell lines compared with their expression in their respective parental cells.
-
cytotoxic assays, stable transfectants of leukemic Jurkat cells overexpressing SLC22A16 cells became significantly more sensitive to doxorubicin
-
Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.
-
that hCT2 can mediate bleomycin-A5 and polyamine uptake, and that the rate of bleomycin-A5 accumulation may account for the differential response to the drug in patients.
-
identification, expression and function of human CT2 as a carnitine transporter in testis mediating transport of l-carnitine
-
Flipts might have a role in carnitine transport, particularly in brain
-
Identification as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias
-
may be possible to use progestins to increase the response of endometrioid endometrial carcinoma with SLC22A16 expression to adriamycin-based chemotherapeutic regimens
-
Exploratory study suggests that the c.146A>G variation could contribute to variations in the pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients.
-
SLC22A16 was abundantly expressed in clear-cell adenocarcinomaof the ovary.
